BLS Pharmaceuticals (ASX: BLS) has signed a referral agreement with US-based Cayman Chemical Company, expanding its international commercial network for pharmaceutical-grade psychedelic medicines and strengthening its position as a manufacturer of regulated MDMA and psilocybin products. The agreement establishes a commercial referral framework under which Cayman Chemical will introduce prospective customers seeking finished pharmaceutical dosage […]
Already subscribed? Log in
US-listed BioAdaptives, Inc. (OTCID: BDPT) has signed a definitive agreement to acquire Xycota Biosciences LLC, a privately held biotechnology company developing experimental psychedelic medicines for psychiatric and neurological...
Canadian biotechnology company PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) has signed an agreement with Corealis Pharma Inc., a contract development and manufacturing organisation based in Laval,...
Definium Therapeutics (NASDAQ: DFTX) is set to present findings from three positive Phase 3 clinical trials of its LSD-based drug candidate, DT120 ODT, at the 2026 Neuroscience Education...
New preclinical findings suggest EB-003 can alter brain activity without producing some of the adverse neurological effects observed with DMT in mice. Enveric Biosciences (NASDAQ: ENVB) has reported...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
